Phase II study of the adjuvant use of lenalidomide in patients undergoing reduced intensity conditioning allogenic transplantation for multiple myeloma.
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 13 Jul 2017
At a glance
- Drugs Lenalidomide (Primary) ; Antithymocyte globulin; Ciclosporin; Fludarabine
- Indications Graft-versus-host disease; Multiple myeloma
- Focus Therapeutic Use
- Acronyms LenaRIC
- 11 Jul 2017 Planned End Date changed from 30 Jun 2015 to 19 Dec 2017.
- 11 Jul 2017 Status changed from completed to active, no longer recruiting.
- 06 Dec 2016 Results (n=40) presented at the 58th Annual Meeting and Exposition of the American Society of Hematology.